Market Cap 97.22M
Revenue (ttm) 78.23M
Net Income (ttm) -21.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.53%
Debt to Equity Ratio -2.07
Volume 860,900
Avg Vol 132,444
Day's Range N/A - N/A
Shares Out 10.13M
Stochastic %K 61%
Beta -0.88
Analysts Sell
Price Target $17.99

Company Profile

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 267 364 3500
Fax: 267 395 2119
Address:
777 Township Line Road, Suite 300, Yardley, United States
UgoGreg
UgoGreg Jun. 22 at 12:35 PM
$OPTN https://youtu.be/7e6vpjWFYZM
0 · Reply
TwongStocks
TwongStocks May. 20 at 8:36 PM
$OPTN Equity Corporate Actions Alert #2025 - 255 Information Regarding the Merger of OptiNose, Inc. (OPTN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-255 Trading in OPTN epxected to halt at 7:50pm ET tonight. Merger with $PRTK expected to close May 21. Trading in OPTN will be suspended effective May 22. "At a special meeting held on May 16, 2025, the shareholders of OptiNose, Inc. (OPTN) approved the proposed merger with Paratek Pharmaceuticals, Inc. (PRTK) and Orca Merger Sub, Inc., a wholly owned subsidiary of Paratek. The merger is tentatively scheduled to close prior to the market open on May 21, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 20, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (May 21st) and will be suspended effective May 22, 2025."
0 · Reply
JarvisFlow
JarvisFlow May. 19 at 11:00 AM
HC Wainwright & Co. has adjusted their stance on OptiNose ( $OPTN ), setting the rating to Neutral with a target price of 9.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 19 at 10:51 AM
WATCHLIST MAY 19 2025. $FYBR Federal Communications Commission Approves Verizon's $20B Acquisition Of Frontier Communications After Verizon Drops Diversity Policies $GIBO GIBO Reveals Upcoming Launch Of GIBO Create-to-Earn Module To Empower Monetization Of AI Animation And Creative Content Within Its Ecosystem $ORCL Oracle Health, Cleveland Clinic, And G42 Announce Strategic Partnership To Develop AI-based Healthcare Delivery Platform $CC Chemours Company Announces Strategic Agreement With DataVolt To Further Demonstrate, Develop Advanced Liquid Cooling Solutions For Data Centers $OPTN HC Wainwright & Co. Reiterates Neutral on OptiNose, Maintains $9 Price Target
0 · Reply
Mergerbrief
Mergerbrief May. 16 at 12:06 PM
$OPTN / Paratek Pharmaceuticals – Shareholder Vote $OPTN
0 · Reply
Estimize
Estimize May. 15 at 10:00 AM
$OPTN reported - EPS and - revenue for Q1. http://www.estimize.com/intro/optn?chart=historical&metric_name=eps&utm_content=OPTN&utm_medium=
0 · Reply
Estimize
Estimize May. 12 at 10:03 AM
Wall St is expecting -0.74 EPS for $OPTN Q1 [Reporting 05/15 BMO] http://www.estimize.com/intro/optn?chart=historical&metric_name=eps&utm_c
0 · Reply
ChessGM
ChessGM May. 8 at 5:07 PM
$OPTN "Heads up alert! Only one day until Upcoming earnings on 5/12/2025 for $OPTN Consensus Signal: Bullish (8.3) In the analysis of OptiNose (OPTN), recent performance metrics showcase a company with a promising growth trajectory. For the fourth quarter of 2024, OPTN reported a narrower-than-expected loss of $360,000, indicating a significant earnings surprise of 95.71%. This is a positive indicator, especially against the backdrop of revenue figures that topped estimates by 5.57%, with reported net revenues of $22.4 million for the quarter and $78.2 million for the full year. The 13% increase in net revenue for XHANCE and a robust 23% growth in prescriptions from Q3 to Q4 highlight strong product demand and market penetration. The P/E ratio remains a critical metric for comparison, and while specific figures may vary, the positive earnings revisions suggest an optimistic outlook. Analysts project a substantial upside potential of 143.06% based on average price targets, reflecting confidence in the stock's future performance. Overall, these metrics signal a company well-positioned for growth in the competitive pharmaceutical landscape. Upcoming earnings reports are anticipated to provide further insights, with analysts closely examining the potential impacts of recent operational highlights on future profitability. Historical performance has shown a consistent improvement in revenue and prescription growth, leading to a consensus estimate that supports a positive outlook. The upcoming earnings call will likely focus on strategic initiatives to sustain momentum and address any operational challenges. Analysts recommend closely monitoring these developments, as they could significantly influence investor sentiment and the stock's price trajectory in the near term. - Funds were net sellers of $OPTN during the previous reporting quarter. - Top 3 funds with large holdings in $OPTN: * Nantahala Capital Management LLC $7MM. CGMFundRank: 66%, Fund Website: www.nantahalapartners.com * Stonepine Capital Management LLC $4MM. CGMFundRank: 73%, Fund Website: www.stonepinecap.com * Great Point Partners LLC $2MM. CGMFundRank: 63%, Fund Website: www.gppfunds.com - Last 10 days performance: 1% - Last 30 days performance: 3% - Last 90 days performance: 57% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
0 · Reply
sam92
sam92 Apr. 24 at 9:41 PM
$OPTN Super positive merger they all should be this way ! LSEG Stocks Plus Report Latest Report 04/24/2025 LSEG maintains a current price target of $18 for OPTN https://archive.fast-edgar.com/20250423/ABBOI62C8W22GZZZ272N2ZZZRMDLZ2V2Z272/
0 · Reply
sam92
sam92 Apr. 23 at 5:59 PM
$OPTN LSEG Stocks Plus Report Latest Report 04/22/2025 LSEG maintains a current price target of $18 for OPTN
0 · Reply
Latest News on OPTN
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Mar 19, 2025, 9:45 PM EDT - 3 months ago

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call


Optinose Announces 1-for-15 Reverse Stock Split

Dec 26, 2024, 7:00 AM EST - 6 months ago

Optinose Announces 1-for-15 Reverse Stock Split


OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 12:47 PM EST - 8 months ago

OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript


Optinose Appoints Terry Kohler as Chief Financial Officer

Oct 7, 2024, 4:59 PM EDT - 9 months ago

Optinose Appoints Terry Kohler as Chief Financial Officer


OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 7:17 AM EDT - 11 months ago

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript


OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript

May 17, 2024, 8:55 PM EDT - 1 year ago

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript


OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 9:14 AM EST - 1 year ago

OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript


OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 10:04 AM EST - 1 year ago

OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript


OptiNose: The Worst Has Been Avoided (Rating Upgrade)

Aug 1, 2023, 6:58 PM EDT - 2 years ago

OptiNose: The Worst Has Been Avoided (Rating Upgrade)


Optinose to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 1:00 PM EDT - 2 years ago

Optinose to Present at the Jefferies Healthcare Conference


OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript

May 11, 2023, 5:57 PM EDT - 2 years ago

OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript


OptiNose, Inc. (OPTN) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 2:22 PM EST - 2 years ago

OptiNose, Inc. (OPTN) Q4 2022 Earnings Call Transcript


Optinose Announces CEO Transition and Business Update

Jan 31, 2023, 7:00 AM EST - 2 years ago

Optinose Announces CEO Transition and Business Update


Optinose Appoints Paul Spence as Chief Commercial Officer

Dec 15, 2022, 4:30 PM EST - 2 years ago

Optinose Appoints Paul Spence as Chief Commercial Officer


UgoGreg
UgoGreg Jun. 22 at 12:35 PM
$OPTN https://youtu.be/7e6vpjWFYZM
0 · Reply
TwongStocks
TwongStocks May. 20 at 8:36 PM
$OPTN Equity Corporate Actions Alert #2025 - 255 Information Regarding the Merger of OptiNose, Inc. (OPTN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-255 Trading in OPTN epxected to halt at 7:50pm ET tonight. Merger with $PRTK expected to close May 21. Trading in OPTN will be suspended effective May 22. "At a special meeting held on May 16, 2025, the shareholders of OptiNose, Inc. (OPTN) approved the proposed merger with Paratek Pharmaceuticals, Inc. (PRTK) and Orca Merger Sub, Inc., a wholly owned subsidiary of Paratek. The merger is tentatively scheduled to close prior to the market open on May 21, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 20, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (May 21st) and will be suspended effective May 22, 2025."
0 · Reply
JarvisFlow
JarvisFlow May. 19 at 11:00 AM
HC Wainwright & Co. has adjusted their stance on OptiNose ( $OPTN ), setting the rating to Neutral with a target price of 9.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 19 at 10:51 AM
WATCHLIST MAY 19 2025. $FYBR Federal Communications Commission Approves Verizon's $20B Acquisition Of Frontier Communications After Verizon Drops Diversity Policies $GIBO GIBO Reveals Upcoming Launch Of GIBO Create-to-Earn Module To Empower Monetization Of AI Animation And Creative Content Within Its Ecosystem $ORCL Oracle Health, Cleveland Clinic, And G42 Announce Strategic Partnership To Develop AI-based Healthcare Delivery Platform $CC Chemours Company Announces Strategic Agreement With DataVolt To Further Demonstrate, Develop Advanced Liquid Cooling Solutions For Data Centers $OPTN HC Wainwright & Co. Reiterates Neutral on OptiNose, Maintains $9 Price Target
0 · Reply
Mergerbrief
Mergerbrief May. 16 at 12:06 PM
$OPTN / Paratek Pharmaceuticals – Shareholder Vote $OPTN
0 · Reply
Estimize
Estimize May. 15 at 10:00 AM
$OPTN reported - EPS and - revenue for Q1. http://www.estimize.com/intro/optn?chart=historical&metric_name=eps&utm_content=OPTN&utm_medium=
0 · Reply
Estimize
Estimize May. 12 at 10:03 AM
Wall St is expecting -0.74 EPS for $OPTN Q1 [Reporting 05/15 BMO] http://www.estimize.com/intro/optn?chart=historical&metric_name=eps&utm_c
0 · Reply
ChessGM
ChessGM May. 8 at 5:07 PM
$OPTN "Heads up alert! Only one day until Upcoming earnings on 5/12/2025 for $OPTN Consensus Signal: Bullish (8.3) In the analysis of OptiNose (OPTN), recent performance metrics showcase a company with a promising growth trajectory. For the fourth quarter of 2024, OPTN reported a narrower-than-expected loss of $360,000, indicating a significant earnings surprise of 95.71%. This is a positive indicator, especially against the backdrop of revenue figures that topped estimates by 5.57%, with reported net revenues of $22.4 million for the quarter and $78.2 million for the full year. The 13% increase in net revenue for XHANCE and a robust 23% growth in prescriptions from Q3 to Q4 highlight strong product demand and market penetration. The P/E ratio remains a critical metric for comparison, and while specific figures may vary, the positive earnings revisions suggest an optimistic outlook. Analysts project a substantial upside potential of 143.06% based on average price targets, reflecting confidence in the stock's future performance. Overall, these metrics signal a company well-positioned for growth in the competitive pharmaceutical landscape. Upcoming earnings reports are anticipated to provide further insights, with analysts closely examining the potential impacts of recent operational highlights on future profitability. Historical performance has shown a consistent improvement in revenue and prescription growth, leading to a consensus estimate that supports a positive outlook. The upcoming earnings call will likely focus on strategic initiatives to sustain momentum and address any operational challenges. Analysts recommend closely monitoring these developments, as they could significantly influence investor sentiment and the stock's price trajectory in the near term. - Funds were net sellers of $OPTN during the previous reporting quarter. - Top 3 funds with large holdings in $OPTN: * Nantahala Capital Management LLC $7MM. CGMFundRank: 66%, Fund Website: www.nantahalapartners.com * Stonepine Capital Management LLC $4MM. CGMFundRank: 73%, Fund Website: www.stonepinecap.com * Great Point Partners LLC $2MM. CGMFundRank: 63%, Fund Website: www.gppfunds.com - Last 10 days performance: 1% - Last 30 days performance: 3% - Last 90 days performance: 57% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
0 · Reply
sam92
sam92 Apr. 24 at 9:41 PM
$OPTN Super positive merger they all should be this way ! LSEG Stocks Plus Report Latest Report 04/24/2025 LSEG maintains a current price target of $18 for OPTN https://archive.fast-edgar.com/20250423/ABBOI62C8W22GZZZ272N2ZZZRMDLZ2V2Z272/
0 · Reply
sam92
sam92 Apr. 23 at 5:59 PM
$OPTN LSEG Stocks Plus Report Latest Report 04/22/2025 LSEG maintains a current price target of $18 for OPTN
0 · Reply
sam92
sam92 Apr. 15 at 3:52 PM
$OPTN Latest Report 04/13/2025 LSEG maintains a current price target of $18 for OPTN
0 · Reply
sam92
sam92 Apr. 10 at 8:29 PM
$OPTN Latest Report 04/10/2025 LSEG maintains a current price target of $18 for OPTN
0 · Reply
sam92
sam92 Apr. 7 at 2:57 PM
$OPTN Latest Report 04/04/2025 LSEG maintains a current price target of $18 for OPTN
0 · Reply
CrayP
CrayP Apr. 4 at 9:21 AM
$OPTN A read of the proxy shows they turned down $15-$20 per share deals while they knew their numbers were coming down only to refinance and dilute to buy themselves time just to give up and sell for a 30-40% discount to prior offers months later....jeeeez
0 · Reply
CrayP
CrayP Apr. 3 at 12:38 PM
$OPTN CEO walks away with a minimum $5M Golden Parachute
0 · Reply
CrayP
CrayP Apr. 3 at 11:42 AM
$OPTN usually use a few percent positive... So, basically discounting at the cost of capital minus the perpetual growth rate which would normally come out to low-to-mid teens rate but here 40-50%. Never seen that before even under the most optimistic set of forecasts. Only way to justify this transaction at less than 50% of the expected purchase price when compared to public and take-private valuations.
0 · Reply
CrayP
CrayP Apr. 3 at 11:41 AM
$OPTN "Evercore performed a discounted cash flow analysis of the Company to calculate ranges of implied present values of the per share equity value of the Company utilizing estimates of the standalone unlevered, after-tax free cash flows that the Company was forecasted to generate over the period from June 1, 2025 through December 31, 2034 based on the March 2025 financial forecasts. Evercore calculated terminal values for the Company by applying a range of perpetuity growth rates of negative 20% to negative 40%, which range was selected based on Company management guidance and Evercore’s professional judgment and experience, to an estimate of the unlevered, after-tax free cash flows that the Company was forecasted to generate in the terminal year based on the March 2025 financial forecasts."
0 · Reply
mmtiddy
mmtiddy Apr. 1 at 6:50 PM
$ALDX They have done this with $XFOR $AKBA $HUMA $OPTN I will not fall for these games shorts
1 · Reply
sam92
sam92 Apr. 1 at 3:25 PM
$OPTN Latest Report 03/30/2025 LSEG maintains a current price target of $18 for OPTN
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 1:43 AM
$OPTN Digging XHANCE potential. ENT specialist market looks promising. Slower uptake but long-term play. Watching closely for insurance coverage improvements. Might add small position if dips. compelling writeup: https://beyondspx.com/article/optinose-navigating-the-chronic-sinusitis-opportunity-with-specialty-focus
0 · Reply
Estimize
Estimize Mar. 26 at 10:06 PM
$OPTN reported -0.03 EPS and 22.42 revenue for Q4. http://www.estimize.com/intro/optn?chart=historical&metric_name=eps&utm_content=OPTN&utm
0 · Reply